On November 16, 2026 Renaissance Pharma Limited (Renaissance Pharma), an Essential Pharma company focused on development stage assets, reported that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for use of daretabart (hu14.18K322A) in combination with induction chemotherapy, for the first-line treatment of paediatric patients with newly diagnosed high-risk neuroblastoma (HRNB).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
This designation was supported by Phase II data published in the Journal of Clinical Oncology in December 20211. The study was an open label, single arm Phase II trial at one centre in 64 children with newly diagnosed HRNB. Three-year event-free survival (EFS) was 73.7% (95% CI 60.0 to 83.4) and three-year overall survival (OS) was 86.0% (95% CI 73.8 to 92.8). Grade 3 or 4 toxicities attributed to the antibody infusion during induction included pain (10% of 379 cycles), hypoxia (6%), infusion related reactions (4%), hypotension (3%) and cough (1%).
The FDA’s BTD program is intended to expedite the development and review of investigational medicines with clinical evidence that may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints.
Simon Ball, President of Renaissance Pharma said, "We look forward to executing our clinical development strategy, including our ongoing SHINE study in relapsed and refractory disease, together with our future planned induction study, to bring this antibody to the neuroblastoma community."
About Daretabart (Hu14.18K322A)
Daretabart (hu14.18K322A) is an anti-GD2 monoclonal antibody in development for the treatment of high-risk neuroblastoma (HRNB), a rare paediatric cancer. Daretabart is being developed by Renaissance Pharma under an exclusive license agreement with St. Jude Children’s Research Hospital, a global leader in paediatric cancer research and treatment. The antibody targets GD2, a cell surface antigen highly expressed on neuroblastoma cells.
About Neuroblastoma
Neuroblastoma is the most common extracranial solid tumour in children and the most common cancer in children under one year of age. Each year, more than 1,500 people are diagnosed in Europe and approximately 800 in the United States. Approximately half of all neuroblastoma patients have high risk (HRNB) disease for which the long-term survival rates from the time of diagnosis are still only around 50%. The current standard of care is intensive and multimodal, including chemotherapy, surgery, radiotherapy, stem cell transplantation and anti-GD2 monoclonal antibody (mAb) treatment. Despite these interventions, a significant unmet medical need persists in HRNB, with survival remaining lower than in other risk group.
(Press release, Renaissance Pharma, NOV 16, 2026, View Source [SID1234674792])